0.40
+0.0133(+3.40%)
Currency In USD
Address
3675 Market St.
Philadelphia, PA 19104
United States of America
Phone
484 899 0326
Website
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
February 06, 2014
| Name | Title | Pay | Year Born |
| Mr. Steven Kelly | President, Chief Executive Officer & Director | 864,750 | 1965 |
| Mr. Michael Klichinsky Ph.D., Pharm.D., PharmD | Co-Founder & Chief Scientific Officer | 619,150 | 1990 |
| Ms. Natalie McAndrew | Vice President of Finance | 0 | 1972 |
| Dr. Saar Gill M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.